The announcement was made after market hours on Friday, 5 July 2013.
Meanwhile, the S&P BSE Sensex was down 235.78 points or 1.21% at 19,260.04.
On BSE, 2,749 shares were traded in the counter as against average daily volume of 42,384 shares in the past one quarter.
The stock was volatile. The stock lost as much as 4.08% at the day's low of Rs 102.20 far during the day. The stock rose as much as 2.67% at the day's high of Rs 109.40 so far during the day. The stock had hit a 52-week high of Rs 152.45 on 17 April 2013. The stock had hit a 52-week low of Rs 78.50 on 18 October 2012.
The stock had underperformed the market over the past one month till 5 July 2013, sliding 14.66% compared with the Sensex's 0.37% fall. The scrip had also underperformed the market in past one quarter, declining 5.2% as against Sensex's 5.67% gain.
The small-cap company has equity capital of Rs 15.82 crore. Face value per share is Re 1.
Fresenius Kabi Oncology said that the company has received a warning letter from the United States Food and Drug Administration (USFDA), inter-alia, asking for certain information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations in respect of the company's API plant located at Nadia district in West Bengal. Earlier, on 26 February 2013, Fresenius Kabi said that the USFDA as part of its routine inspection made certain observations relating to GMP non-conformities in respect of manufacturing, documentation practices and product testing at the company's API plant at Nadia subsequent to which the company at that time has voluntarily put the production at the plant on hold.
Fresenius Kabi Oncology reported net loss of Rs 7.76 crore in Q4 March 2013 as against net profit of Rs 1.68 crore in Q4 March 2012. Net sales declined 32.6% to Rs 70.54 crore in Q4 March 2013 over Q4 March 2012.
Fresenius Kabi Oncology develops, manufactures and markets anti-cancer products for critically and chronically ill patients. Besides the unit in West Bengal, the company has another manufacturing unit at Baddi in Himachal Pradesh.
The company is also engaged in research and development of anti-cancer products.
Powered by Capital Market - Live News
